Isis discontinues development of ISIS-CRPRx for rheumatoid arthritis

08/6/2013 | Reuters

Isis Pharmaceuticals is halting development of its investigational drug ISIS-CRPRx as a treatment for rheumatoid arthritis based on the findings of a Phase II study. The drug failed to significantly outperform a placebo in the alleviation of symptoms. The firm will continue to develop the drug for other diseases, including atrial fibrillation.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health